Akebia Therapeutics, Inc. - COMMON STOCK (AKBA) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
AKBA on Nasdaq
Shares outstanding
263,222,327
Price per share
$1.40
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
94,970,266
Total reported value
$152,908,898
% of total 13F portfolios
0%
Share change
-2,893,876
Value change
-$8,245,841
Number of holders
118
Price from insider filings
$1.40
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Akebia Therapeutics, Inc. - COMMON STOCK (AKBA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.2% +18% $30,943,909 +$6,565,662 19,219,819 +27% BlackRock, Inc. 31 Dec 2025
STATE STREET CORP 5.2% $19,162,585 13,687,561 STATE STREET CORPORATION 31 Dec 2025
VANGUARD GROUP INC 5.4% $23,849,310 12,685,803 The Vanguard Group 31 Mar 2025
Satter Muneer A 2.6% $10,806,063 5,747,906 Satter Muneer A 31 Dec 2024

As of 31 Dec 2025, 118 institutional investors reported holding 94,970,266 shares of Akebia Therapeutics, Inc. - COMMON STOCK (AKBA). This represents 36% of the company’s total 263,222,327 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Akebia Therapeutics, Inc. - COMMON STOCK (AKBA) together control 33% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 7.3% 19,318,452 +2.8% 0% $31,102,707
VANGUARD GROUP INC 6.1% 16,016,448 +3% 0% $25,786,481
STATE STREET CORP 5.2% 13,687,561 +16% 0% $22,036,973
GEODE CAPITAL MANAGEMENT, LLC 2.4% 6,277,177 +1.5% 0% $10,107,969
GOLDMAN SACHS GROUP INC 1.8% 4,706,437 +166% 0% $7,577,364
RENAISSANCE TECHNOLOGIES LLC 1.4% 3,593,133 -9.1% 0.01% $5,784,944
CITIGROUP INC 0.93% 2,436,203 +27% 0% $3,922,287
ACADIAN ASSET MANAGEMENT LLC 0.84% 2,199,747 +2.4% 0.01% $3,539,000
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.83% 2,180,820 +0.49% 0% $3,511,120
Nantahala Capital Management, LLC 0.76% 2,000,000 0% 0.19% $3,220,000
HRT FINANCIAL LP 0.62% 1,619,336 +6430% 0.01% $2,607,000
DIMENSIONAL FUND ADVISORS LP 0.6% 1,571,012 -11% 0% $2,528,891
FEDERATED HERMES, INC. 0.49% 1,291,172 +102% 0% $2,078,787
MORGAN STANLEY 0.47% 1,228,816 -72% 0% $1,978,394
Squarepoint Ops LLC 0.46% 1,223,027 +57% 0% $1,969,073
FIRST TRUST ADVISORS LP 0.36% 941,657 0% $1,516,067
BARCLAYS PLC 0.35% 923,507 -22% 0% $1,486,847
UBS Group AG 0.33% 871,534 -76% 0% $1,403,170
Connor, Clark & Lunn Investment Management Ltd. 0.29% 753,906 -26% 0% $1,213,789
NORDEA INVESTMENT MANAGEMENT AB 0.29% 752,106 0% $1,214,651
BNP PARIBAS FINANCIAL MARKETS 0.28% 730,409 0% 0% $1,175,958
JANE STREET GROUP, LLC 0.26% 691,584 +359% 0% $1,113,451
Bank of New York Mellon Corp 0.25% 666,907 -1.8% 0% $1,073,720
JACOBS LEVY EQUITY MANAGEMENT, INC 0.25% 657,812 -0.71% 0% $1,059,077
Nuveen, LLC 0.23% 592,991 -74% 0% $954,716

Institutional Holders of Akebia Therapeutics, Inc. - COMMON STOCK (AKBA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 94,970,266 $152,908,898 -$8,245,841 $1.61 118
2025 Q3 123,688,043 $337,736,101 +$36,363,103 $2.73 177
2025 Q2 108,291,108 $394,183,978 +$56,486,756 $3.64 157
2025 Q1 95,246,755 $182,865,938 +$63,362,980 $1.92 142
2024 Q4 67,840,406 $128,894,660 +$16,358,053 $1.90 120
2024 Q3 59,433,206 $78,447,145 +$882,725 $1.32 115
2024 Q2 56,272,761 $57,425,610 -$2,480,654 $1.02 101
2024 Q1 56,990,819 $104,292,720 +$1,817,015 $1.83 113
2023 Q4 54,644,253 $67,756,733 +$4,178,925 $1.24 82
2023 Q3 50,796,695 $57,905,974 +$685,292 $1.14 71
2023 Q2 50,244,140 $45,972,296 -$1,392,349 $0.92 75
2023 Q1 49,135,498 $27,534,495 +$24,262 $0.56 60
2022 Q4 49,331,303 $28,463,302 +$1,764,966 $0.58 68
2022 Q3 51,102,625 $16,156,537 -$1,544,723 $0.32 71
2022 Q2 52,731,333 $18,605,852 -$7,471,753 $0.35 77
2022 Q1 80,115,766 $57,503,264 -$32,793,134 $0.72 111
2021 Q4 94,948,884 $214,509,331 -$4,438,987 $2.26 122
2021 Q3 91,455,604 $263,401,086 -$28,731,218 $2.88 113
2021 Q2 100,599,566 $381,269,872 +$8,312,122 $3.79 130
2021 Q1 98,532,848 $333,487,108 -$7,597,939 $3.38 130
2020 Q4 98,251,493 $275,101,582 -$4,620,424 $2.80 126
2020 Q3 97,388,170 $244,391,291 -$415,114,985 $2.51 150
2020 Q2 110,916,330 $1,505,916,765 +$245,724,351 $13.58 180
2020 Q1 81,409,194 $617,084,895 +$70,542,800 $7.58 142
2019 Q4 72,429,305 $457,795,928 -$7,377,480 $6.32 141
2019 Q3 83,329,311 $326,689,202 -$6,475,040 $3.92 138
2019 Q2 86,379,308 $417,937,115 -$1,552,214 $4.84 143
2019 Q1 75,679,052 $619,803,378 +$32,892,240 $8.19 158
2018 Q4 71,162,972 $393,287,213 +$199,373,087 $5.53 148
2018 Q3 40,803,315 $360,267,694 -$21,325,807 $8.83 123
2018 Q2 42,400,184 $423,106,024 -$3,992,749 $9.98 135
2018 Q1 42,823,466 $408,778,819 +$77,938,784 $9.53 143
2017 Q4 33,437,817 $497,165,737 +$18,742,919 $14.87 125
2017 Q3 29,916,828 $588,376,151 +$66,361,130 $19.67 115
2017 Q2 27,264,438 $391,607,872 +$96,239,505 $14.37 113
2017 Q1 20,824,499 $191,428,543 +$23,086,723 $9.20 84
2016 Q4 20,196,557 $210,228,267 +$3,874,697 $10.41 89
2016 Q3 19,221,631 $173,890,259 -$250,528 $9.05 81
2016 Q2 19,605,579 $146,637,724 -$12,713,544 $7.48 90
2016 Q1 21,112,430 $190,508,000 +$34,259,238 $9.01 90
2015 Q4 15,822,049 $204,382,610 +$34,814,470 $12.92 86
2015 Q3 13,586,460 $131,233,918 +$22,247,113 $9.66 79
2015 Q2 10,556,959 $108,626,881 +$58,466,170 $10.29 67
2015 Q1 6,123,004 $68,027,761 -$4,502,448 $11.11 56
2014 Q4 6,518,091 $75,862,339 -$6,538,454 $11.64 53
2014 Q3 5,604,905 $124,036,296 +$8,038,610 $22.13 48
2014 Q2 6,582,196 $182,917,396 +$180,868,346 $27.79 48
2014 Q1 103,803 $2,030,000 +$2,030,003 $19.56 3